Shanghai Henlius Biotech Co. Ltd.
https://www.henlius.com/en/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Henlius Biotech Co. Ltd.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
BeiGene Among Chinese Firms Eyeing Less Crowded SCLC Sector In US Trials
BeiGene, Junshi, Henlius are studying their PD-1, TIGIT and BTLA-targeting assets in US trials for the relatively less crowded indication of small cell lung cancer.
Henlius Announces Positive Phase I/II Results For Ophthalmic Bevacizumab Biosimilar
Henlius has successfully established the safety and preliminary efficacy of its ophthalmology-indicated bevacizumab biosimilar HLX04-O in Phase I/II trials.
Henlius Sees Revenues Soar In 2022, Q1 2023, As New Plant Bears Fruit
Chinese player Shanghai Henlius Biotech has published unaudited financial results for the first three months of 2023, in the wake of its 2022 annual report.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Fosun Pharma
- Henlius Biopharmaceuticals
- Shanghai Henlius Biotech, Inc.
- Taiwan Henlix Biotech Co., Ltd.
- Hengenix Biotech
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice